These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 22559147)

  • 41. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunotherapy of lung cancer: an update.
    Rüttinger D; Winter H; van den Engel NK; Hatz RA; Schlemmer M; Pohla H; Grützner S; Schendel DJ; Fox BA; Jauch KW
    Onkologie; 2006 Feb; 29(1-2):33-8. PubMed ID: 16514254
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunotherapy for Lung Cancer.
    Reinmuth N; Reck M
    Oncol Res Treat; 2016; 39(6):360-8. PubMed ID: 27259861
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunotherapy of metastasis.
    Dallal RM; Lotze MT
    Surg Oncol Clin N Am; 2001 Apr; 10(2):433-47, xi. PubMed ID: 11382596
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Current immunotherapeutic strategies in lung cancer.
    Rüttinger D; Hatz RA; Jauch KW; Fox BA
    Surg Oncol Clin N Am; 2007 Oct; 16(4):901-18, x. PubMed ID: 18022551
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combination strategies for enhancing the efficacy of immunotherapy in cancer patients.
    Moschella F; Proietti E; Capone I; Belardelli F
    Ann N Y Acad Sci; 2010 Apr; 1194():169-78. PubMed ID: 20536466
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunotherapy for small-cell lung cancer: emerging evidence.
    Reck M; Heigener D; Reinmuth N
    Future Oncol; 2016 Apr; 12(7):931-43. PubMed ID: 26882955
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antitumor vaccination: where we stand.
    Bocchia M; Bronte V; Colombo MP; De Vincentiis A; Di Nicola M; Forni G; Lanata L; Lemoli RM; Massaia M; Rondelli D; Zanon P; Tura S
    Haematologica; 2000 Nov; 85(11):1172-206. PubMed ID: 11074658
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Active specific immunotherapy and cell-transfer therapy for the treatment of non-small cell lung cancer.
    Kakimi K; Nakajima J; Wada H
    Lung Cancer; 2009 Jul; 65(1):1-8. PubMed ID: 19062127
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C; Sanda MG
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Utilization of the Immune System in Lung Cancer Treatment: Beyond Chemotherapy.
    Chan CW; Tsui SK; Law BM; So WK; Tang FW; Wong CL
    Int J Mol Sci; 2016 Feb; 17(3):286. PubMed ID: 26927069
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cancer vaccines: an update with special focus on ganglioside antigens.
    Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE
    Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunotherapy in non-small-cell lung carcinoma: from inflammation to vaccination.
    Van den Heuvel MM; Burgers SA; van Zandwijk N
    Clin Lung Cancer; 2009 Mar; 10(2):99-105. PubMed ID: 19362952
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cancer immunotherapy.
    Schuster M; Nechansky A; Kircheis R
    Biotechnol J; 2006 Feb; 1(2):138-47. PubMed ID: 16892244
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy.
    Gridelli C; Rossi A; Maione P; Ferrara ML; Castaldo V; Sacco PC
    Oncologist; 2009 Sep; 14(9):909-20. PubMed ID: 19726457
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New strategies in lung cancer: translating immunotherapy into clinical practice.
    Forde PM; Kelly RJ; Brahmer JR
    Clin Cancer Res; 2014 Mar; 20(5):1067-73. PubMed ID: 24470514
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy.
    Bodey B; Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 2000; 20(4):2665-76. PubMed ID: 10953341
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Boosting immune responses in lung tumor immune microenvironment: A comprehensive review of strategies and adjuvants.
    Gao F; You X; Yang L; Zou X; Sui B
    Int Rev Immunol; 2024; 43(5):280-308. PubMed ID: 38525925
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer.
    Nemunaitis J; Dillman RO; Schwarzenberger PO; Senzer N; Cunningham C; Cutler J; Tong A; Kumar P; Pappen B; Hamilton C; DeVol E; Maples PB; Liu L; Chamberlin T; Shawler DL; Fakhrai H
    J Clin Oncol; 2006 Oct; 24(29):4721-30. PubMed ID: 16966690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.